A61K39/025

Method of treating protozoal gastrointestinal disorders in immunocompromised patients
10478493 · 2019-11-19 · ·

The invention relates to a method for treating protozoal gastrointestinal disorders in immunocompromised patients. It includes a method for the isolation of a factor from the milk of hyperimmunized animals in a substantially pure form, and to the use of said factor in combination with vitamins and minerals.

KLEBSIELLA PNEUMONIAE STRAIN THAT INDUCES INFLAMMATION IN THE LIVER

To identify a microorganism causing the development of primary sclerosing cholangitis associated with ulcerative colitis. A Klebsiella pneumoniae strain inducing inflammation in the liver.

VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONS
20240131135 · 2024-04-25 ·

Disclosed herein are vaccine compositions for the treatment and prevention of urinary tract infections (UT!s) and methods for delivery of the vaccine compositions. Moreover, the disclosure provides adjuvant compositions for vaccines to modulate cellular responses. such as an immune response.

Triple vaccine protects against bacterial and fungal pathogens via trained immunity

An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

METHOD AND KIT FOR QUANTIFYING VACCINE
20190293650 · 2019-09-26 ·

The present disclosure provides a method for quantifying a vaccine. The method includes the steps of: 1) providing a plurality of standard mixtures, each of the standard mixtures having a standard antigen and an aluminum based adjuvant; 2) mixing a stabilizing solution with the vaccine and each of the standard mixtures; 3) determining dosages of the standard antigens in the standard mixtures to establish a standard curve; and 4) determining a dosage of a target antigen in the vaccine according to the standard curve.

Chemical Synthesis Method of Plesiomonas Shigelloides Serotype O51 O-antigen Oligosaccharide
20190233459 · 2019-08-01 ·

The present disclosure discloses the chemical synthesis method of the Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide, belonging to the field of chemistry. Source-abundant D-glucose, L-fucose, D-glucosamine and the like are used as raw materials to prepare three glycosylation building blocks, the synthetic route composed of 11 reaction modules is designed, and through the optimization of protecting group and the optimization of the time of introducing functional group, the preparation of the target oligosaccharide chain is successfully achieved. The oligosaccharide chain prepared in the present disclosure has the advantages of cheap and easy-to-get raw materials, and simple and easy-to-repeat preparation method. The present disclosure will have good application prospects in the aspects of development of new drugs and vaccines of Plesiomonas shigelloides, and the like.

LIVE ATTENUATED EDWARDSIELLA ICTALURI VACCINE AND METHOD OF USING THE SAME

A live attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpB protein and a method of using the same to protect fish against infection from virulent Edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent Edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated Edwardsiella ictaluri bacterium lacking a viable gene encoding a functional protein selected from the group consisting of evpB, fur and hfq. The bacterium may include an insertion and/or deletion mutation in the gene. The fish include catfish, preferably catfish fingerling or a catfish fry. The composition may be delivered via immersion delivery, an injection delivery, an oral delivery, or combinations thereof.

FimH mutant, compositions therewith and use thereof

Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.

<i>Lactococcus lactis </i>subspecies lactis isolate WFLU-12 and use thereof

The present invention provides a Lactococcus lactis subspecies lactis isolate WFLU-12 with the accession number o KCTC 13180BP, and a use thereof.

Compounds and methods for biofilm disruption and prevention

The invention relates to compounds, compositions and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial deoxyribonucleases.